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Studies have shown that anti-HLA donor speciﬁc antibodies
are detrimental in solid organ transplantations. However,
their roles in hematopoietic stem cell transplantation (HSCT)
have not been fully studied. The aim of our study was to
investigate the levels of anti-HLA donor speciﬁc antibodies
(DSA) and their impact on graft outcome in HSCT.
Patients and Methods: 49 recipients of allogeneic HSCTwith
anti-HLA DSA pre-transplant were included in the study
between July, 2006 and July, 2012. All patients (pts) were
screened foranti-HLAantibodiesusingLABScreenPRAand/or
LABScreen Mixed kits. And antibody speciﬁcity analysis was
conducted for screening positive patients using LABScreen
Single Antigen beads on Luminex platform method (One
Lambda Inc., CanogaPark, CA). Resultswere expressed asmean
ﬂuorescence intensity (MFI) with MFI  500 considered posi-
tive. Sera from initial testing and the time of transplant (Tx) for
each patient were included in the analysis. Pretransplant
specimens with the highest MFI were used in the analysis.
Results:Majority of pts who had anti-HLA DSAwere females
(91.8%). The transplant donors included in three categories:
16 haplo-identical, 12 double umbilical cord blood units
(DCBU), and 21 unrelated donors. More class II DSAs (67%)
were observed than class I (33%). HLA-DPB1 only DSA
accounted for 48.8%. Forty-three of the 49 patients had DSA
at the time of Txt. Of the 43 pts, 27 had DSA <5,000 MFI, 10
had DSA >5,000 MFI, and 6 had DSA >10,000 MFI. Early
death occurred in 4 pts (3 had DSA <5,000 MFI, 1 had DSA
>5,000 MFI). Seven pts developed rejection/primary GF, 6
pts had secondary GF within 100 days of transplantation and
9 pts had mixed chimerism. Of the 7 pts with rejection/
primary GF, 3 were haplo-identical Tx (all DSA >5,000 MFI)
and 4 were unrelated (2 with DSA <5,000 MFI and 2 with
DSA >5,000 MFI). The rate of rejection/primary GF was
higher in pts who had DSA >5,000 MFI (5/15) compared to
those DSA <5,000 MFI (2/24) (P ¼ .0846). While in contrast,
more pts with secondary GF within 100 days (5/6) or mixed
chimerism (8/9) had DSA <5,000 MFI (P ¼ .3461, P ¼ .21,
respectively). Of the 6 pts with secondary GF, 1 had haplo-
identical Tx (DSA <5,000 MFI), 2 unrelated (DSA <5,000
MFI), and 3 DCBU (1 DSA >5,000 MFI, 2 DSA <5,000 MFI).
Conclusion: At least moderate DSA (MFI >5,000) seemed
more frequently to result in rejection/primary graft failure
while secondary GF/mixed chimerism could be associated
more with lower DSA levels (MFI<5,000) suggesting that DSA
could be a predisposing factor for these to develop in the
appropriate setting (e.g. reduced-intensity conditioning). Over
half of the pts with rejection/primary or secondary GF hadDSA
toHLA-DPB1only (7/13). This suggested thatmatching atDPB1
locuscouldbeas importantasmatching inotherHLAloci. These
results suggest that avoidance of DSA evenwith lowMFI levels
could be essential for improving graft outcome in HSCT pts.470
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Background: While CB transplantation (CBT) recipients are
at signiﬁcant risk for CMV infection, the course of this
infection after CBT is not well understood.
Methods: We examined the incidence, nature, risk factors &
outcomes of CMV infection in 154 double-unit CBT recipients
transplanted between 10/2005 & 5/2012. Patients received
low dose acyclovir as prophylaxis & were monitored for CMV
reactivation in the blood by antigenemia assay or qPCR. End-
organ disease was diagnosed by standard criteria. Addition-
ally, patients with severe pulmonary compromise in the
setting of viremia not fulﬁlling criteria for CMV pneumonia
were deﬁned as CMV pulmonary syndrome.
Results: 154 patients [median age 41 years (range 0.9-69),
median weight 67 kg (range 8-125), 83 (54%) CMV seropos-
itive] were transplanted for hematological malignancies with
myeloablative (n ¼ 118, 77%) or non-myeloablative (n ¼ 36,
23%) conditioning & calcineurin-inhibitor/mycophenolate
mofetil immunosuppression. No patient received anti-
thymocyte globulin. CB grafts were 4-6/6 HLA-A,B antigen,
-DRB1 allele matched to the recipient. CMV reactivation was
restricted to CMV seropositive patients. Of CMV+ CBT recip-
ients monitored by antigenemia (n ¼ 56), 37 (66%) patients
reactivated (median onset 40 days, range -1-294). Of these,
7/37 (19%) developed diseasewith their initial reactivation: 1
pneumonia (onset 58 days), 1 pulmonary syndrome (onset
39 days), & 5 gastrointestinal (GI) disease (median onset 54
days, range 49-67). Notably, all 27 CMV+ patients monitored
by PCR reactivated at a median of 33 days (range 3-64). Of
these, 4/27 (15%) patients developed CMV disease (1 pneu-
monia & 3 pulmonary syndrome) at a median of 38 days
(range 10-56). None had GI disease with their initial infec-
tion. In Cox regression analysis including patient age, diag-
nosis, conditioning intensity, engrafting unit infused CD34+
dose & engrafting unit-recipient HLA-match, no factor was
associated with the risk of severe initial CMV infection
(disease or pulmonary syndrome). Recurrent infection has
been observed in 29 patients, to date, with reactivation
occurring in the context of GVHD and its therapy in 19/29
(66%) patients. With a median 34 months (range 5-79)
follow-up of CMV+ patients, CMV infection has caused (n¼ 2,
both pneumonia) or contributed (n ¼ 7) to death in a total of
9 of the 83 (11%) CMV+ patients, with 7/9 deaths occurring
with the initial CMV infection.
Conclusions: CMV infection remains a major cause of
morbidity & mortality in seropositive CBT recipients. PCR
surveillance permits earlier detection of reactivation but
whether this improves the clinical outcome requires further
investigation. CMV-associated lung disease, in particular,
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& therapy, and studies of the determinants of CMV-speciﬁc
immune recovery, are a priority for this patient population.
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Allogeneic hematopoietic stem cell transplant (HCT) is
a curative therapy for sickle cell disease (SCD). However,
majority of patients lack a matched sibling or unrelated
donor. The use of a partially matched related donor would
provide donors for majority of the patients. We report the
results of 8 consecutive pediatric patients with SCD who had
a prior stroke, who underwent a T cell depleted HLA-hap-
loidentical HCT using a reduced intensity conditioning
regimen without total body irradiaiton. The median age was
75 yrs (4-17) with the median follow up of 73 yrs (3-9).
The ﬁrst 3 patients received ﬂudarabine (150-200 mg/m2),
thiotepa (10mg/kg), targeted busulfan (900 ng/ml for 4 d),
rabbit antithymocyte globulin (rATG) (10mg/kg x 3 d), and
OKT3 (0.1mg/kgmaximum over d +1 to +20). The subsequent
5 patients received busulfan (900ng/ml x 4 d), thiotepa
(10mg/kg), cyclophosphamide (200 mg/kg) and OKT3
(0.1mg/kg max on d-10 to +17) as well as mycophenolate
mofetil for graft versus host (GVHD) prophylaxis. The
product consisted of a CD34+ selected product infused on d0
and a CD3+ depleted product infused on d+1. The infused
products had a mean total nucleated cell (TNC) of 450680 x
106 kg (10-1890), CD34+ cells of 25.416.3 x 106/kg (6-57)
and CD3+ cells of 0.070.07 x 106/kg (0.006-0.168). All 8
patients achieved donor engraftment with a median of 12
d (10-14). Donor engraftment was maintained in 5 patients,
with one patient requiring a second stem cell infusion. TheTable 1
Patients and donors characteristics
Patient
number
Age
(years)
Sex Donor
Age
(years)
Donor
Sex
Source of
Progenitor
Age
Dif
(ye
1 6 Male 62 Male PB 56
2 5 Male 60 Female PB 55
3 2.5 Female 45 Female BM 42.
4 5.5 Female 63 Male PB 57.
5 7 Male 75 Female PB 68
6 2 Female 60 Female PB 58
7 11 Male 69 Male PB 58
8 8.5 Female 68 Male PB 59.
9 9.5 Female 46 Female BM 36.
10 2 Male 48 Female BM 46
11 1 Male 74 Male PB 73
12 9 Male 62 Male PB 53
13 0.25 Female 71 Male PB 70.
PB: Peripheral Blood, BM: BoneMarrow, ALL: Acute Lymphoblastic Leukemia, TM: T
CD4 dif: CD4 deﬁciency, AML: Acute Myeloid Leukemia, MPS: Mucopolysaccharidomedian time to rejection for the 4 patients was 30 d (22-44)
after HSCT. Of the 5 engrafted patients, 4 patients developed
acute GVHD (3 with grade I-II and 1 with Grade III). Of the 5
engrafted patients, 3 developed chronic GVHD (1 with
limited and 2 with extensive). The 2 patients with extensive
GVHD died of complication of GVHD. The 3 surviving
patients have been transfusion independent with no
evidence of SCD related complications. Indices of hemolysis
decreased after HCT with decreased reticulocyte count, bili-
rubin and LDH. Themedian hemoglobin increased from9.6
0.6 to 13.6  2. Renal and cardiac were stable after HCT. MRI
showed no new infarct or vessel occlusion. In summary, 3
patients survived free of SCD, 2 engrafted but died of
complications from GVHD and 3 had recurrent SCD after
graft rejection. Despite good outcomes in 3 of the 8 patients,
rejection, chronic GVHD and transplant related mortality
were signiﬁcant problems. Recently, Bolaños-Meade et al.
published the result of haploidentical HCT for SCD using
post-transplant cyclophosphamide. Both regimens encoun-
tered graft failure, however GVHD and mortality was not as
prevalent as our report. Though limited, our data suggest
that for patients with SCD, graft-versus-host disease
prophylaxis after haploidentical HCT with high dose cyclo-
phosphamide may be a safer regimen and further studies are
warranted.
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Background: HLA matching is one of the most important
factors affecting patients' prognosis after hematopoietic
stem cell transplantation (HSCT). Currently when there are
no HLA-match siblings, transplantation centers try to ﬁnd
unrelated HLA-matched donor through bone marrow and
cord blood registries. However, few studies showed that
searching extended families such as parents, grandparents,
aunts and uncles for an appropriate donor is useful.
Methods: This is a retrospective study from our center in
which the patients who underwent HSCT of any diseases
and their grandparents were as donors included in the
study. The principal data including graft-versus-host-diseaseference
ars)
Disease Acute
GVHD
Chronic
GVHD
Patient Status
ALL Yes No Full chimerism/Alive
TM II Yes No Full chimerism/Alive
5 LAD I Yes Yes Full chimerism/Alive
5 FA Yes No Full chimerism/Alive
TM II Yes No Rejected/Dead
AML No No Rejected/Alive
FA No No Full chimerism/Alive
5 CD4 dif. Yes Yes Full chimerism/Alive
5 AML Yes No Rejected/Dead
MPS I Yes No Full chimerism/Alive
LAD I Yes Yes Full chimerism/Alive
TM III No No Rejected/Alive
75 SCID Yes No Full chimerism/Alive
halassemia Major, LAD: Leukocyte Adhesion Deﬁciency, FA: Fanconi Anemia,
ses, SCID: Severe Combined Immunodeﬁciency.
